Computationally-guided drug repurposing enables the discovery of kinase targets and inhibitors as new schistosomicidal agents.

ABSTRACT: The development of novel therapeutics is urgently required for diseases where existing treatments are failing due to the emergence of resistance. This is particularly pertinent for parasitic infections of the tropics and sub-tropics, referred to collectively as neglected tropical diseases, where the commercial incentives to develop new drugs are weak. One such disease is schistosomiasis, a highly prevalent acute and chronic condition caused by a parasitic helminth infection, with three species of the genus Schistosoma infecting humans. Currently, a single 40-year old drug, praziquantel, is available to treat all infective species, but its use in mass drug administration is leading to signs of drug-resistance emerging. To meet the challenge of developing new therapeutics against this diseas

SUBMITTER: Giuliani S 

PROVIDER: S-EPMC6211772 | biostudies-literature | 2018 Oct

REPOSITORIES: biostudies-literature